Emergence of antimicrobial resistance among Acinetobacter species: A global threat

Current Opinion in Critical Care

Volumn 22, Issue 5, 2016, Pages 491-499

  Clark, Nina M ^a   Zhanel, George G ^b   Lynch, Joseph P ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acinetobacter baumannii; Acinetobacter spp.; antimicrobial resistance; carbapenemases; clonal spread; multidrug resistance; plasmids

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIN; QUINOLONE DERIVATIVE; RIFAMPICIN; SULBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; COHORT ANALYSIS; DRUG MECHANISM; HUMAN; INFECTION CONTROL; MICROBIOLOGY; MOLECULAR CLONING; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; CROSS INFECTION; DRUG EFFECTS; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS;

EID: 84983340506     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000337     Document Type: Review

References (91)

1. Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: Evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 2015; 36:85-98.
2. Jones CL, Clancy M, Honnold C, et al. Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence. Clin Infect Dis 2015; 61:145-154.
3. Davis JS, McMillan M, Swaminathan A, et al. A 16-year prospective study of community-onset bacteremic Acinetobacter pneumonia: Low mortality with appropriate initialempirical antibiotic protocols. Chest 2014;146:1038-1045.
4. Lee YT, Kuo SC, Yang SP, et al. Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis: A single or two distinct clinical entities? Clin Microbiol Infect 2013; 19:640-645.
5. Freire MP, de Oliveira Garcia D, Garcia CP, et al. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: High mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect 2016; 22:352-358.
6. Ozgur ES, Horasan ES, Karaca K, et al. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: Risk factors, clinical features, and outcomes. Am J Infect Control 2014; 42:206-208.
7. Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 2016; 47:317-323.
8. Tokajian S, Eisen JA, Jospin G, et al. Draft genome sequences of Acinetobacter baumannii strains harboring the blaNDM-1 gene isolated in Lebanon from civilians wounded during the Syrian civil war. Genome Announc 2016; 4:e01678-15.
9. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317.
10. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gramnegative bacilli. Clin Infect Dis 2005; 41:848-854.
11. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis 2014; 78:443-448.
12. Viana GF, Zago MC, Moreira RR, et al. ISAba1/bla: A serious obstacle to controlling the spread and treatment of Acinetobacter baumannii strains. Am J Infect Control 2016; 44:593-595.
13. Chung DR, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011; 184:1409-1417.
14. Teo J, Lim TP, Hsu LY, et al. Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: A molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrob Resist Infect Control 2015; 4:2.
15. Garnacho-Montero J, Dimopoulos G, Poulakou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med 2015; 41:2057-2075.
16. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: Clinical impact and therapeutic options. Int J Antimicrob Agents 2012; 39:105-114.
17. Garnacho-Montero J, Gutierrez-Pizarraya A, Diaz-Martin A, et al. Acinetobacter baumannii in critically ill patients: Molecular epidemiology, clinical features and predictors of mortality. Enferm Infecc Microbiol Clin 2016. [Epub ahead of print]
18. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-2329.
19. Wisplinghoff H, Paulus T, Lugenheim M, et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect 2012; 64:282-290.
20. Chuang YC, Sheng WH, Li SY, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis 2011; 52:352-360.
21. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358:1271-1281.
22. Turkoglu M, Mirza E, Tunccan OG, et al. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: Risk factors and impact on mortality. J Crit Care 2011; 26:460-467.
23. Chiang MC, Kuo SC, Chen SJ, et al. Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors. Infection 2012; 40:19-26.
24. Fukuta Y, Muder RR, Agha ME, et al. Risk factors for acquisition of multidrugresistant Acinetobacter baumannii among cancer patients. Am J Infect Control 2013; 41:1249-1252.
25. Huang ST, Chiang MC, Kuo SC, et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2012; 45:356-362.
26. Hsu JF, Chu SM, Lien R, et al. Case-control analysis of endemic Acinetobacter baumannii bacteremia in the neonatal intensive care unit. Am J Infect Control 2014; 42:23-27.
27. Gavalda L, Soriano AM, Camara J, et al. Control of endemic extensively drugresistant Acinetobacter baumannii with a cohorting policy and cleaning procedures based on the 1 room, 1 wipe approach. Am J Infect Control 2016; 44:520-524.
28. Reichel M, Schlicht A, Ostermeyer C, Kampf G. Efficacy of surface disinfectant cleaners against emerging highly resistant gram-negative bacteria. BMC Infect Dis 2014; 14:292.
29. Perumal PK, Wand ME, Sutton JM, Bock LJ. Evaluation of the effectiveness of hydrogen-peroxide-based disinfectants on biofilms formed by Gram-negative pathogens. J Hosp Infect 2014; 87:227-233.
30. Peleg AY, de Breij A, Adams MD, et al. The success of acinetobacter species; genetic, metabolic and virulence attributes. PLoS One 2012; 7:46984.
31. Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. Int J Antimicrob Agents 2015; 45:568-585.
32. Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int 2014; 2014:249856.
33. Kim Y, Bae IK, Lee H, et al. In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment. Diagn Microbiol Infect Dis 2014; 79:362-366.
34. Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii: Clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67:1607-1615.
35. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Acinetobacter baumannii 2002-2008: Increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010; 16:209-215.
36. Queenan AM, Pillar CM, Deane J, et al. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: Results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis 2012; 73:267-270.
37. Jones RN, Guzman-Blanco M, Gales AC, et al. Susceptibility rates in Latin American nations: Report from a regional resistance surveillance program (2011). Braz J Infect Dis 2013; 17:672-681.
38. Lee MH, Chen TL, Lee YT, et al. Dissemination of multidrug-resistant Acinetobacter baumannii carrying BlaOxA-23 from hospitals in central Taiwan. J Microbiol Immunol Infect 2013; 46:419-424.
39. Lee HS, Loh YX, Lee JJ, et al. Antimicrobial consumption and resistance in five Gram-negative bacterial species in a hospital from 2003 to 2011. J Microbiol Immunol Infect 2015; 48:647-654.
40. Nordmann P, Picazo JJ, Mutters R, et al. Comparative activity of carbapenem testing: The COMPACT study. J Antimicrob Chemother 2011; 66:1070-1078.
41. Turner PJ. Meropenem activity against European isolates: Report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008; 60:185-192.
42. Wareham DW, Bean DC, Khanna P, et al. Bloodstream infection due to Acinetobacter spp: Epidemiology, risk factors and impact of multidrug resistance. Eur J Clin Microbiol infect Dis 2008; 27:607-612.
43. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66:2070-2074.
44. Xu A, Zheng B, Xu YC, et al. National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013. Clin Microbiol infect 2016; 22:S1-S8.
45. Kuo SC, Lee YT, Yang SP, et al. Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia. Clin Microbiol Infect 2013; 19:634-639.
46. Ogutlu A, Guclu E, Karabay O, et al. Effects of carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients. Ann Clin Microbiol Antimicrob 2014; 13:7.
47. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: Mechanisms and epidemiology. Clin Microbiol Infect 2006; 12:826-836.
48. Oliveira MS, Prado GV, Costa SF, et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008; 61:1369-1375.
49. Jaruratanasirikul S, Wongpoowarak W, Aeinlang N, Jullangkoon M. Pharmacodynamics modeling to optimize dosage regimens of sulbactam. Antimicrob Agents Chemother 2013; 57:3441-3444.
50. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56:432-436.
51. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol 2011; 19:588-595.
52. Fu Y, Jiang J, Zhou H, et al. Characterization of a novel plasmid type and various genetic contexts of bla OXA-58 in Acinetobacter spp. from multiple cities in China. PLoS One 2014; 9:e84680.
53. Merino M, Poza M, Roca I, et al. Nosocomial outbreak of a multiresistant Acinetobacter baumannii expressing OXA-23 carbapenemase in Spain. Microb Drug Resist 2014; 20:259-263.
54. Mezzatesta ML, Caio C, Gona F, et al. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: Considerations on in vitro assay of active drugs. Int J Antimicrob Agents 2014; 44:112-116.
55. Adams-Haduch JM, Onuoha EO, Bogdanovich T, et al. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol 2011; 49:3849-3854.
56. Robledo IE, Aquino EE, Sante MI, et al. Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob Agents Chemother 2010; 54:1354-1357.
57. Poirel L, Bonnin RA, Boulanger A, et al. Tn125-related acquisition of blaNDMlike genes in Acinetobacter baumannii. Antimicrob Agents Chemother 2012; 56:1087-1089.
58. Karthikeyan K, Thirunarayan MA, Krishnan P. Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. J Antimicrob Chemother 2010; 65:2253-2254.
59. Zhang R, Hu YY, Yang XF, et al. Emergence of NDM-producing nonbaumannii Acinetobacter spp. isolated from China. Eur J Clin Microbiol infect Dis 2014; 33:853-860.
60. Nakazawa Y, Ii R, Tamura T, et al. A case of NDM-1-producing Acinetobacter baumannii transferred from India to Japan. J Infect Chemother 2013; 19:330-332.
61. Ghazawi A, Sonnevend A, Bonnin RA, et al. NDM-2 carbapenemase-producing Acinetobacter baumannii in the United Arab Emirates. Clin Microbiol Infect 2012; 18:E34-E36.
62. Pagano M, Poirel L, Martins AF, et al. Emergence of NDM-1-producing Acinetobacter pittii in Brazil. Int J Antimicrob Agents 2015; 45:444-445.
63. Gottig S, Gruber TM, Higgins PG, et al. Detection of pan drug-resistant Acinetobacter baumannii in Germany. J Antimicrob Chemother 2014; 69:2578-2579.
64. Lesho EP, Waterman PE, Chukwuma U, et al. The antimicrobial resistance monitoring and research (ARMoR) program: The US Department of Defense response to escalating antimicrobial resistance. Clin Infect Dis 2014; 59:390-397.
65. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistinassociated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53:879-884.
66. De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 2014; 18:R90.
67. Leporati M, Bua RO, Mariano F, et al. Determination by LC-MS/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration. Ther Drug Monit 2014; 36:182-191.
68. Garnacho J, Sole-Violan J, Sa-Borges M, et al. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: A matched cohort study. Crit Care Med 2003; 31:2478-2482.
69. Chen YM, Fang WF, Kao HC, et al. Influencing factors of successful eradication of multidrug-resistant Acinetobacter baumannii in the respiratory tract with aerosolized colistin. Biomed J 2014; 37:314-320.
70. Shields RK, Clancy CJ, Gillis LM, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 2012; 7:e52349.
71. Rolain JM, Roch A, Castanier M, et al. Acinetobacter baumannii resistant to colistin with impaired virulence: A case report from France. J Infect Dis 2011; 204:1146-1147.
72. Lopez-Rojas R, Dominguez-Herrera J, McConnell MJ, et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 2011; 203:545-548.
73. Hoban DJ, Reinert RR, Bouchillon SK, Dowzicky MJ. Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013. Ann Clin Microbiol Antimicrob 2015; 14:27.
74. Colton B, McConeghy KW, Schreckenberger PC, Danziger LH. I.V. minocycline revisited for infections caused by multidrug-resistant organisms. Am J Health System Pharm 2016; 73:279-285.
75. Hua X, Chen Q, Li X, Yu Y. Global transcriptional response of Acinetobacter baumannii to a subinhibitory concentration of tigecycline. Int J Antimicrob Agents 2014; 44:337-344.
76. Ku K, Pogue JM, Moshos J, et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenemresistant Enterobacteriaceae infections. Am J Infect Control 2012; 40:983-987.
77. Lee YT, Tsao SM, Hsueh PR. Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 2013; 32:1211-1220.
78. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/ cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68:140-151.
79. Chuang YC, Cheng CY, Sheng WH, et al. Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: A matched cohort analysis. BMC Infect Dis 2014; 14:102.
80. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699-1709.
81. Lesho E, Chukwuma U, Sparks M, et al. Anatomic, geographic, and taxaspecific relative risks of carbapenem resistance in the healthcare system of the U.S. Department of Defense. J Clin Microbiol 2016; 54:1546-1551.
82. Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013; 141:1214-1222.
83. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: A multicenter, randomized clinical trial. Clin Infect Dis 2013; 57:349-358.
84. Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014; 33:1311-1322.
85. Lopez-Cortes LE, Cisneros JM, Fernandez-Cuenca F, et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: Analysis of a multicentre prospective cohort. J Antimicrob Chemother 2014; 69:3119-3126.
86. Cheng A, Chuang YC, Sun HY, et al. Excess mortality associated with colistintigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: A multicenter prospective observational study. Crit Care Med 2015; 43:1194-1204.
87. Garnacho-Montero J, Amaya-Villar R, Gutierrez-Pizarraya A, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy 2013; 59:225-231.
88. Petrosillo N, Giannella M, Antonelli M, et al. Clinical experience of colistinglycopeptide combination in critically ill patients infected with gram-negative bacteria. Antimicrob Agents Chemother 2014; 58:851-858.
89. Lysakowska ME, Ciebiada-Adamiec A, Klimek L, SienkiewiczM. The activity of silver nanoparticles (Axonnite) on clinical and environmental strains of Acinetobacter spp. Burns 2015; 41:364-371.
90. Martinez-Resendez MF, Garza-Gonzalez E, Mendoza-Olazaran S, et al. Impact of daily chlorhexidine baths and hand hygiene compliance on nosocomial infection rates in critically ill patients. Am J Infect Control 2014; 42:713-717.
91. Sambanthamoorthy K, Feng X, Patel R, et al. Antimicrobial and antibiofilm potential of biosurfactants isolated from lactobacilli against multidrug-resistant pathogens. BMC Microbiol 2014; 14:197.